Achieving approval for a psychedelic-assisted therapy (PAT) would be a significant milestone. However, given the complexities and costs associated with PATs, they won’t fit neatly into the existing healthcare system. There are a variety of challenges that will need to be addressed in order to achieve meaningful access to PATs, which will entail engaging a diverse range of stakeholders: from…

Source

Previous articleNuminus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Next articlePharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome